EGFR and coronary artery disorder: For patients in stage C/D, coronary heart disease (χ2 = 7.36, P = 0.007), LV hypertrophy (χ2 = 11.09, P = 0.004), systolic dysfunction (χ2 = 186.76, P < 0.001), and diastolic dysfunction (χ2 = 43.74, P < 0.001) accounted for more than a half and were significantly higher than in patients in stage B. The proportion of patients with EGFR <60 ml/ (min × 1.73 m2) was significantly greater in stage C/D than in other HF stages (stage C/D 46.7% vs. stage 0 8% vs. stage A 7.6% vs. stage B 15.9%, P < 0.001).